RxDoctor Payments Data

Thanh Ha Luong, MD

Internal Medicine · Bronx, NYNPI 1639351232

Payments from drug & device makers

$11,554in general payments, 2019–2025

Across 490 payments — averaging $23.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Novartis$1K
  • Eisai Inc.$1K
  • Pfizer$807
  • Daiichi Sankyo Inc.$783
  • Merck$626
  • plus $6K from 33 others

What the payments were for

  • Food & beverage$11,24797%
  • Education$3073%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,554 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$21,415
Medicare patients
72
Services billed
178

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LenvimaLenvatinib Mesylate31$746,086
NubeqaDarolutamide47$642,880
ErleadaApalutamide36$508,193
KisqaliRibociclib Succinate24$266,951
ImbruvicaIbrutinib13$212,243
TasignaNilotinib Hcl11$206,346
Abiraterone Acetate51$147,858
EliquisApixaban33$23,798
XareltoRivaroxaban17$22,035
Exemestane48$7,125
Imatinib Mesylate20$6,015
Letrozole236$1,954
Ondansetron Hcl96$1,225
Mometasone Furoate11$1,106
Anastrozole64$596

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Eisai Inc.Lenvima$1,104$746,08631 claims
BayerNubeqa$120$642,88047 claims
Johnson & JohnsonErleada, Xarelto$1,351$530,22853 claims
NovartisKisqali, Tasigna$1,184$473,29735 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$280$212,24313 claims
PfizerEliquis$807$23,79833 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →